Retinol Versus Retinal Versus Adapalene: What the Evidence Map Actually Says

RetinolRetinolStrongRetinol · Vitamin A alcoholThe best-evidenced over-the-counter retinoid for photoageing; now capped at 0.3 % in EU leave-on products.Open in the Index →, RetinalRetinalModerateRetinal · Vitamin A aldehydeOne conversion step from retinoic acid; faster-acting than retinol in the few trials that exist, with good tolerance.Open in the Index → (also called retinaldehyde) and AdapaleneAdapaleneStrongAdapalene · Synthetic third-generation retinoidA prescription-strength retinoid available OTC at 0.1 % in the US; stable, well tolerated, strong acne evidence.Open in the Index → are often shelved together as "retinoids," as if they were three strengths of one thing. The evidence does not support that shorthand. They have different chemistry, have been tested for different purposes, and sit in different legal categories depending on where you live. A fair comparison has to ask two questions at once: evidence for what, and available how?

This map separates the two main uses people care about, visible ageing and acne, and grades each ingredient for each use on The Skindex scale of Strong, Moderate, Limited and Emerging. It is a reading of the published evidence, not treatment guidance.

Three molecules, two different stories

Retinol and retinal belong to the same metabolic chain. After application, retinol is converted to retinal, and retinal is converted to retinoic acid, the form that acts on retinoid receptors in skin cells.¹ Retinoic acid itself is the prescription drug tretinoin. A 2022 focused review summarises the usual pattern: biological activity rises from retinyl esters to retinol to retinal to retinoic acid, while tolerance runs the other way, with retinol and retinal ranked roughly equal and both far better tolerated than retinoic acid.¹

Adapalene is not part of that chain. It is a synthetic retinoid that binds selectively to two of the three retinoic acid receptor subtypes (RAR-beta and RAR-gamma), whereas tretinoin binds all three.² A clinicians' review describes it as the least irritating and least prone to breaking down in light among the topical retinoid drugs.² Calling adapalene "stronger than retinal" or retinal "a gentler adapalene" mixes two different mechanisms.

Photoageing: what the trials show

Retinol: Moderate. The anchor study is a randomised, double-blind, vehicle-controlled trial in 36 older adults (mean age 87). A 0.4% retinol lotion applied to one arm up to three times a week for 24 weeks improved fine wrinkling scores significantly compared with the vehicle-treated arm, and biopsies in a small subgroup showed more glycosaminoglycans and procollagen I.³ A later comparison found that retinol produced the same kinds of changes as retinoic acid in epidermal thickness and collagen-related gene and protein expression, though the effects tended to be smaller; a 12-week facial imaging study then showed a significant reduction in wrinkles with a retinol formulation.⁴ Retinol is the most clinically studied cosmetic retinoid, but the 2022 review notes that many retinol trials are small and lack a vehicle control.¹ That combination supports a real effect on fine lines, with a thinner base than the ingredient's popularity implies.

Retinal: Limited. The foundational human study showed that retinal is biologically active in skin. It raised a marker of retinoid activity (CRABP-2) with potency ranked below retinoic acid and above retinol, and in volunteers using 0.05% to 0.5% for one to three months it increased epidermal thickness in a dose-dependent way. The 0.05% and 0.1% preparations were well tolerated on the face in long-term use.⁵ The key clinical trial randomised 125 people with facial photodamage to 0.05% retinal, 0.05% retinoic acid or vehicle. Wrinkle and roughness measures fell significantly from baseline in both active groups at week 18, with a smaller reduction at week 44, and did not change in the vehicle group. Retinal was well tolerated, while retinoic acid caused more irritation and affected compliance.⁶ However, the 2022 review, reading the trial's results table, reports no statistically significant differences between groups, including retinal versus vehicle.¹ A later 40-person trial compared 0.1% and 0.05% retinal without a vehicle arm.¹ Retinal may well be the most promising cosmetic retinoid, as reviewers suggest, but the controlled clinical evidence is still slim.

Adapalene: Limited, and not at over-the-counter strength. The main comparative study found 0.3% adapalene gel non-inferior to 0.05% tretinoin cream for signs of photoageing over 24 weeks, with a similar safety profile, in an investigator-blinded trial without a vehicle group.⁷ Photoageing is an off-label use of adapalene, and the evidence sits at the 0.3% prescription strength rather than the 0.1% gel.²⁷

A note on a source you may see quoted: a Cochrane review, "Interventions for photodamaged skin," once summarised the tretinoin photodamage trials. It was withdrawn in 2015 under Cochrane's Commercial Sponsorship Policy and should not be cited as a current Cochrane conclusion.⁸

Acne: a different leader

Adapalene: Strong. The American Academy of Dermatology's 2024 acne guideline, built on a systematic review graded with the GRADE method, makes a strong recommendation for topical retinoids.⁹ Adapalene has direct head-to-head trial support. In a 12-week, investigator-masked, randomised trial of 323 patients, 0.1% adapalene gel reduced total lesions by 49% versus 37% for 0.025% tretinoin gel and was significantly better tolerated.¹⁰ In two further multicentre trials with 591 patients, adapalene 0.1% was more effective than tretinoin 0.025% in one and equally effective in the other, and was better tolerated in both.¹¹

Retinal: Emerging. Laboratory work found that retinal directly inhibits Propionibacterium acnes (now called Cutibacterium acnes), and in a small single-blind randomised study daily 0.05% retinal lowered the density of the bacteria on skin over two weeks.¹² That is a plausible mechanism, not a clinical acne outcome, and we found no controlled trials of retinal on acne lesion counts in the sources reviewed.

Retinol: not graded. None of the sources reviewed for this piece tested cosmetic retinol on acne lesions, so we do not assign a grade. That is an absence of evidence in this review, not evidence of no effect.

Three access lanes

How you encounter each ingredient depends on regulation more than on chemistry.

Retinol is a cosmetic ingredient with a new EU cap. Since Commission Regulation (EU) 2024/996, retinol, retinyl acetate and retinyl palmitate are limited in EU cosmetics to 0.05% retinol equivalent in body lotion and 0.3% retinol equivalent in other leave-on and rinse-off products, with the label warning "Contains Vitamin A. Consider your daily intake before use."¹³ The regulation's recitals tie the cap to overall vitamin A intake: the scientific committee judged the cosmetic contribution low, but potentially of concern for the 5% of people with the highest exposure from food and supplements. Non-compliant products could not be placed on the EU market from 1 November 2025, and must be off shelves by 1 May 2027.¹³

Retinal is a cosmetic ingredient not named in that cap. The 2024 regulation lists retinol and two retinyl esters; retinal does not appear in it.¹³ Its evidence and its legal status are therefore separate questions.

Adapalene is a medicine. In the United States, adapalene 0.1% gel moved from prescription to over-the-counter status through an FDA-approved switch of its existing drug application on 8 July 2016, which is a drug approval pathway rather than a cosmetic listing. The 0.3% gel remains prescription only.¹⁴¹⁵ In Canada, Health Canada's Prescription Drug List includes "adapalene or its salts or derivatives," so adapalene products require a prescription there.¹⁶

Summary of the map

• Photoageing: retinol Moderate; retinal Limited; adapalene Limited (0.3%, prescription strength, off-label).
• Acne: adapalene Strong; retinal Emerging; retinol not graded.
• Tolerance: retinol and retinal are ranked similarly and well above retinoic acid; adapalene is better tolerated than tretinoin in acne trials.¹¹⁰¹¹

FAQ

Is retinal "stronger" than retinol?

Biologically, it is one conversion step closer to retinoic acid, and early work ranked its activity above retinol's.⁵¹ Clinically, there is no large head-to-head trial showing retinal outperforms retinol on wrinkles, so "stronger" describes the chemistry more reliably than the results.

Is over-the-counter adapalene an anti-ageing product?

In the US, the 0.1% gel is an over-the-counter acne drug.¹⁴ The photoageing data come mainly from the 0.3% prescription gel and are limited.⁷

Why does the EU cap retinol but not retinal?

The 2024 regulation followed a scientific opinion on vitamin A focused on retinol and two retinyl esters, and it restricts only those three.¹³ Retinal was outside that assessment, which says nothing either way about its safety at a given strength.

Can I trust claims that one of these beats tretinoin?

Look at which comparison was actually run. Retinol produced similar but smaller changes than retinoic acid,⁴ retinal matched it with less irritation on within-group measures,⁶ and adapalene 0.3% was non-inferior on photoageing in one trial.⁷ None of these makes a cosmetic product equivalent to a prescription one.

Where the evidence stops

Retinol has the most clinical data among cosmetic retinoids for fine lines, but that base is modest. Retinal is biologically active and well tolerated, with limited controlled clinical evidence. Adapalene is the only one of the three with strong acne evidence and a drug status to match, and its photoageing evidence is limited and tied to a prescription strength.³⁶¹⁹⁷ Any ranking that ignores those distinctions is a marketing claim, not an evidence map.

Footnotes

1. Milosheska D, Roškar R. Use of Retinoids in Topical Antiaging Treatments: A Focused Review of Clinical Evidence for Conventional and Nanoformulations. Adv Ther. 2022. PMID 36220974. doi:10.1007/s12325-022-02319-7 ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

2. Motamedi M, Chehade A, Sanghera R, et al. A Clinician's Guide to Topical Retinoids. J Cutan Med Surg. 2022. PMC8750127. doi:10.1177/12034754211035091 ↩ ↩² ↩³

3. Kafi R, Kwak HS, Schumacher WE, et al. Improvement of naturally aged skin with vitamin A (retinol). Arch Dermatol. 2007. PMID 17515510. doi:10.1001/archderm.143.5.606 ↩ ↩²

4. Kong R, Cui Y, Fisher GJ, et al. A comparative study of the effects of retinol and retinoic acid on histological, molecular, and clinical properties of human skin. J Cosmet Dermatol. 2016. PMID 26578346. doi:10.1111/jocd.12193 ↩ ↩²

5. Saurat JH, Didierjean L, Masgrau E, et al. Topical retinaldehyde on human skin: biologic effects and tolerance. J Invest Dermatol. 1994. PMID 7798613. doi:10.1111/1523-1747.ep12412861 ↩ ↩²

6. Creidi P, Vienne MP, Ochonisky S, et al. Profilometric evaluation of photodamage after topical retinaldehyde and retinoic acid treatment. J Am Acad Dermatol. 1998. PMID 9843009. doi:10.1016/s0190-9622(98)70270-1 ↩ ↩² ↩³

7. Bagatin E, Gonçalves HS, Sato M, et al. Comparable efficacy of adapalene 0.3% gel and tretinoin 0.05% cream as treatment for cutaneous photoaging. Eur J Dermatol. 2018. PMID 30105991. doi:10.1684/ejd.2018.3320 ↩ ↩² ↩³ ↩⁴ ↩⁵

8. Samuel M, Brooke RC, Hollis S, et al. WITHDRAWN: Interventions for photodamaged skin. Cochrane Database Syst Rev. 2015. PMID 26035235. doi:10.1002/14651858.CD001782.pub3 ↩

9. Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024. PMID 38300170. doi:10.1016/j.jaad.2023.12.017 ↩ ↩²

10. Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol. 1996. PMID 8609263. doi:10.1016/s0190-9622(96)90443-0 ↩ ↩²

11. Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Am Acad Dermatol. 1997. PMID 9204091. doi:10.1016/s0190-9622(97)70056-2 ↩ ↩²

12. Pechère M, Pechère JC, Siegenthaler G, et al. Antibacterial activity of retinaldehyde against Propionibacterium acnes. Dermatology. 1999. PMID 10473957. doi:10.1159/000051375 ↩

13. Commission Regulation (EU) 2024/996 of 3 April 2024, recitals 2 and 3 and Annex III entries for Retinol, Retinyl Acetate and Retinyl Palmitate. https://eur-lex.europa.eu/eli/reg/2024/996/oj ↩ ↩² ↩³ ↩⁴

14. U.S. Food and Drug Administration. Drugs@FDA, NDA 020380, Supplement 10 (Efficacy: Rx to OTC Switch), 8 July 2016. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020380 ↩ ↩²

15. U.S. Food and Drug Administration. Drugs@FDA, NDA 021753 (adapalene gel 0.3%), marketing status: Prescription. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021753 ↩

16. Health Canada. Prescription Drug List. https://hpr-rps.hres.ca/pdl-pvu.php ↩